S-Infinity Pharmaceuticals patents new MAP3K8 kinase inhibitors
Jan. 2, 2025
S-Infinity Pharmaceuticals Co. Ltd. has disclosed azaquinoline ring-containing compounds acting as Tpl-2/Cot (MAP3K8) kinase inhibitors reported to be useful for the treatment of cancer, diabetes and inflammatory disorders.